Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
0.93
-0.08 (-7.92%)
At close: May 13, 2025, 11:09 AM
-7.92% (1D)
| Bid | 0.71 |
| Market Cap | 36.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.77M |
| EPS (ttm) | -1.26 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -1.99 |
| Analyst | Buy |
| Ask | 1.16 |
| Volume | 575,593 |
| Avg. Volume (20D) | 382,783 |
| Open | 0.98 |
| Previous Close | 1.01 |
| Day's Range | 0.91 - 0.99 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | 2.91 |
About ITRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-15.87%
Iterum Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
6 months ago
+60.68%
Iterum Therapeutics shares are trading higher after the FDA approved the company's new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections.
